Currently out of the existing stock ratings of Madison El-Saadi, 13 are a BUY (92.86%), 1 are a HOLD (7.14%).

Madison El-Saadi

Work Performance Price Targets & Ratings Chart

Analyst Madison El-Saadi, currently employed at B. RILEY, carries an average stock price target met ratio of 56.67% that have a potential upside of 59.26% achieved within 151 days.

Madison El-Saadi’s has documented 28 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ETON, Eton Pharmaceuticals at 20-Mar-2026.

Wall Street Analyst Madison El-Saadi

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) at 9/19/2024. The price target of $11 was fulfilled within 27 days with a profit of $5.06 (85.19%) receiving and performance score of 31.55.

Average potential price target upside

AXSM Axsome Therapeutics CAPR Capricor Therapeutics ETON Eton Pharmaceuticals VNDA Vanda Pharmaceuticals WVE Wave Life Sciences Ltd

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 07-Jun-2018

$290

$56.2 (24.04%)

$290

8 days ago
(08-Jul-2026)

44/48 (91.67%)

$44.43 (18.09%)

717

Buy Since 25-Jan-2024

$304

$70.2 (30.03%)

$302

9 days ago
(07-Jul-2026)

19/21 (90.48%)

$54.24 (21.72%)

249

Buy Since 14-Apr-2020

$300

$58.33 (24.14%)

$190

29 days ago
(17-Jun-2026)

11/12 (91.67%)

$47.84 (18.97%)

763

Buy Since 03-Sep-2025

$255

$13.33 (5.52%)

$202

2 months 11 days ago
(05-May-2026)

5/5 (100%)

$31.94 (14.32%)

78

Hold Since 05-May-2026

$242

$0.33 (0.14%)

$204

2 months 11 days ago
(05-May-2026)

6/6 (100%)

$18.94 (8.49%)

181

Show more analysts

Please expand the browser size to see the chart

Which stock is Madison El-Saadi is most bullish on?

Potential upside of $41.49 has been obtained for CAPR (CAPRICOR THERAPEUTICS)

Which stock is Madison El-Saadi is most reserved on?

Potential downside of -$5.61 has been obtained for ETON (ETON PHARMACEUTICALS)

What Year was the first public recommendation made by Madison El-Saadi?

On 2024

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?